UK group raises ethical concerns regarding AI in healthcare

The Nuffield Council on Bioethics, a British independent monitoring body, in a recent briefing note, has expressed concern regarding the ethical implications of artificial intelligence (AI) in healthcare.

"The potential applications of AI in healthcare are being explored through a number of promising initiatives across different sectors—by industry, health sector organizations and through government investment,” said Hugh Whittall, Director of the Nuffield Council on Bioethics. “While their aims and interests may vary, there are some common ethical issues that arise from their work. Our briefing note outlines some of the key ethical issues that need to be considered if the benefits of AI technology are to be realized, and public trust maintained. The challenge will be to ensure that innovation in AI is developed and used in ways that are transparent, that address societal needs, and that are consistent with public values."

AI has the potential to reduce of medical errors, improve patient engagement, eliminate human bias and improve chronic disease management. But ethical concerns include responsibility when AI is used to support decision-making, erroneous decisions from AI, inherent bias in data used to train AI systems and the security and privacy of potentially sensitive data.

“AI technologies have the potential to help address important health challenges but might be limited by the quality of available health data, and by the inability of AI to possess some human characteristics, such as compassion,” concluded the note. “The use of AI raises a number of ethical and social issues, many of which overlap with issues raised by the use of data and healthcare technologies more broadly. A key challenge for future governance of AI technologies will be ensuring that AI is developed and used in a way that is transparent and compatible with the public interest, whilst stimulating and driving innovation in the sector.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.